Alkermes plc. (ALKS) FY2025 10-K Annual Report
Alkermes plc. (ALKS) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 25, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Alkermes plc. FY2025 10-K Analysis
Business Overview
- • Core business model: Pharmaceutical development and licensing for specialty medicines, with substantial collaboration and royalty revenues from partners Janssen and Biogen
- • Strategic shift: Sale of Athlone manufacturing facility in May 2024 and transition of VUMERITY manufacturing to Biogen's subcontractor completed August 2025
- • Notable litigation: Multiple patent infringement lawsuits filed in 2025 against generic challengers to LYBALVI, triggering FDA approval stays via Hatch-Waxman Act
- • R&D expenses increased sharply to $324M in 2025 from $245M in 2024, driven largely by development of Alixorexton
- • Unique tax impact: First full year affected by new EU minimum corporate tax of 15% effective January 1, 2024, with no material effect reported on 2025 taxes
Management Discussion & Analysis
- • Revenue product sales, net $1,184.6M up $101.1M YoY from $1,083.5M, driven by LYBALVI (+$66.7M) and ARISTADA (+$23.8M) growth
- • Manufacturing and royalty revenues declined $182.8M to $291.3M, mainly from long-acting INVEGA products down $126.9M
- • Net income $241.7M vs $372.1M, due to $84.9M expense increase and $182.8M lower manufacturing/royalty revenues
- • Operating margin not specified; product sales gross margin impacted by $1,027.9M gross-to-net adjustments (46.4% of gross sales)
- • Cash use: $10M acquisition costs for Avadel adding LUMRYZ product; no capex, buyback, or dividend details disclosed
- • Risks: generic VIVITROL entry in 2027, patent litigation for LYBALVI, competitive pressure on core products; expanded commercial portfolio post Avadel acquisition with LUMRYZ
Risk Factors
- • Regulatory risk: potential increased tax liability of ~$70M on $965.7M in cumulative unremitted U.S. earnings upon repatriation subject to foreign tax credits and withholding
- • Macroeconomic threat: $1.525B senior secured term loans due 2031 with interest margins of 1.75%-2.75% increase financing costs and leverage post-Avadel Acquisition
- • Supply chain vulnerability: $43.7M decrease in cost of goods sold due to Athlone Facility sale in May 2024, impacting legacy product manufacturing capacity
- • Competitive risk: product sales dependent on ARISTADA, LYBALVI, VIVITROL with Medicaid rebates and chargebacks impacting gross-to-net adjustments by $316M at 2025 year-end
- • Financial risk: 17.1% effective tax rate in 2025 exceeding 12.5% Irish statutory rate driven by nondeductible expenses and higher-taxable income segments impacting net margins
Alkermes plc. FY2025 Key Financial MetricsXBRL
Revenue
$1.5B
▼ -5.2% YoY
Net Income
$242M
▼ -34.2% YoY
Operating Margin
17.2%
▼ -980bp YoY
Net Margin
16.4%
▼ -719bp YoY
ROE
13.3%
▼ -1177bp YoY
Total Assets
$2.5B
▲ +21.0% YoY
EPS (Diluted)
$1.43
▼ -34.1% YoY
Operating Cash Flow
$521M
▲ +18.6% YoY
Source: XBRL data from Alkermes plc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Alkermes plc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.